Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) (1A11) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
|Description||Phosphoinositidine 3-kinase (PI3K) targets phosphoinositide lipids for phosphorylation at the D-3 position to serve as a second messenger molecule to activate signaling pathways in response to extracellular stimuli. Akt/protein kinase B (PKB) is a major downstream target of PI3K. The multiple forms of PI3K have different specificities and different affinities for various phosphatidylinositol forms. The PH domains of downstream proteins in these pathways bind to these secondary messengers, causing altered cellular distribution and subsequent kinase activation. The PI3K/Akt pathway is altered in a large proportion of human cancers, as this pathway regulates cellular survival, cell cycle progression, and cell growth.|
|Applications||Flow Cytometry, WB|
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat, and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr458 of human phospho PI3K p85|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Phosphatidylinositol 3-kinase regulatory subunit alpha, PIK3R1, GRB1, Phosphatidylinositol 3-kinase regulatory subunit beta, PIK3R2, Phosphatidylinositol 3-kinase regulatory subunit gamma, PIK3R3, p55PIK|
|References||Franke TF, Kaplan DR, and Cantley LC. (1997) Cell. 88: 435-437.
Fresno JAV, Casado E, Cejas P, et al. (2004) Cancer Treatment Reviews. 30: 193-204.
Flow cytometric analysis of Ramos cells secondary antibody only negative control (blue) or untreated (red) or treated with pervanadate (green) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11. Cat.#2066.
Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or treated with imatinib (red) or with pervanadate (green) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11 at 0.1 µg/mL. Cat #2066.
Peptide blocking flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (light blue) or treated with imatinib (red) or with pervanadate (green) or imatinib and blocked with phospho-peptide (black) or pervanadate and blocked with phospho peptide (gold) or imatinib and blocked with non-phospho peptide (dark blue) or pervanadate and blocked with non-phospho peptide (purple) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11 at 0.1 µg/mL. Cat #2066.
Western blot analysis of NIH3T3 cell extract, untreated or treated with UV using 0.5 ug/mL Phospho-PI3Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11. Cat #2066.